Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Area of Science:

• Genetics and Molecular Biology
• Biotechnology
• Medical Research

Background:

• Gene therapy shows promise for treating genetic diseases, with recent FDA approvals for conditions like Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy.
• Current gene therapy approaches, including in situ and ex vivo methods, have limitations in targeting specific tissues.
• In vivo gene therapy trials encounter challenges such as immune responses, the need for immunosuppressants leading to infections, and unpredictable overexpression effects.

Purpose of the Study:

• To critically evaluate the current landscape of gene therapy for genetic diseases.
• To identify and address the challenges and risks associated with gene therapy, including viral delivery system adverse outcomes.
• To provide tools and resources for informed decision-making and to guide future gene therapy development, ensuring its continued success.

Main Methods:

• Review of current gene therapy applications and FDA-approved treatments.
• Analysis of challenges encountered in in situ, ex vivo, and in vivo gene therapy trials.
• Assessment of risks associated with viral delivery systems, such as hepatotoxicity and lethality.

Main Results:

• Despite successes, gene therapy's application risks overextension into unsuitable genetic diseases.
• In vivo gene therapy faces significant hurdles including immune reactions, immunosuppression side effects, and tissue-specific correction difficulties.
• Viral vectors can cause severe adverse events, necessitating careful risk-benefit evaluation for each genetic condition.

Conclusions:

• A thorough cost-benefit analysis is essential for determining the appropriate use of gene therapy across diverse genetic diseases.
• Addressing challenges like immune response and delivery system safety is critical for the responsible advancement of gene therapy.
• Developing strategic tools and resources will help navigate potential issues and ensure the sustainable success of the gene therapy field.